Market
Story
FDA Approves January 26, 2025, Monthly Maintenance Dosing for Eisai/Biogen's lecanemab-irmb in Early Alzheimer's Treatment
Jan 27, 2025, 02:46 AM
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer's disease. This decision, announced on January 26, 2025, allows for intravenous administration of the drug developed by Eisai Co. Ltd. and Biogen. The approval signals a significant advancement in the treatment options available for early-stage Alzheimer's patients, providing a new avenue for ongoing management of the disease.
View original story
Similar markets
Other • 25%
No clear market leader • 25%
LEQEMBI leads market • 25%
Competitor drug leads market • 25%
Donanemab leads • 25%
Leqembi leads • 25%
Both have equal share • 25%
Other treatments lead • 25%
Eisai/Biogen • 25%
Other • 25%
No clear leader • 25%
Eli Lilly • 25%
Other companies • 25%
No dominant company • 25%
Eli Lilly • 25%
Eisai and Biogen • 25%
10% to 20% • 25%
Less than 5% • 25%
5% to 10% • 25%
More than 20% • 25%
Roche • 25%
Pfizer • 25%
Eli Lilly • 25%
Other • 25%
20% to 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
More than 30% • 25%
No • 50%
Yes • 50%
Withdrawn by manufacturer • 25%
Rejected by FDA • 25%
Pending approval • 25%
FDA approved and in market • 25%
Less than 10% • 25%
20% to 30% • 25%
10% to 20% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%